LBA12 Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II study

Qing Zhou, Yi‐Long Wu, Liang Sun et al.|Annals of Oncology|2023

Cited by 10